Having trouble accessing articles? Reset your cache.

Aldeyra reports Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported data from a Phase IIa trial showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease compared to baseline. The trial enrolled 51 patients

Read the full 347 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers